FY2026 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Analysts at Leerink Partnrs lifted their FY2026 earnings per share (EPS) estimates for REGENXBIO in a research report issued on Tuesday, May 27th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($1.65) per share for the year, up from their previous estimate of ($1.69). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2027 earnings at ($3.16) EPS, FY2028 earnings at ($2.59) EPS and FY2029 earnings at ($1.76) EPS.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). The company had revenue of $89.01 million during the quarter, compared to analysts’ expectations of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%.

Other research analysts also recently issued research reports about the company. Chardan Capital reiterated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. The Goldman Sachs Group cut their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, April 17th. Leerink Partners set a $24.00 target price on REGENXBIO in a research note on Tuesday, March 18th. Wall Street Zen raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Finally, Morgan Stanley raised their target price on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, March 14th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus target price of $31.63.

REGENXBIO Trading Down 3.2%

RGNX opened at $8.68 on Friday. The company has a market cap of $435.39 million, a P/E ratio of -1.73 and a beta of 1.11. The business’s 50-day moving average price is $7.88 and its 200-day moving average price is $7.94. REGENXBIO has a 12 month low of $5.04 and a 12 month high of $15.36.

Institutional Trading of REGENXBIO

Several institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. lifted its holdings in REGENXBIO by 67.0% in the fourth quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock worth $31,975,000 after buying an additional 1,659,206 shares during the period. Vanguard Group Inc. lifted its holdings in REGENXBIO by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company’s stock worth $24,832,000 after buying an additional 487,036 shares during the period. Millennium Management LLC lifted its holdings in REGENXBIO by 406.3% in the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock worth $10,222,000 after buying an additional 1,061,187 shares during the period. Balyasny Asset Management L.P. lifted its holdings in REGENXBIO by 6.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company’s stock worth $9,176,000 after buying an additional 66,993 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in REGENXBIO by 1.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company’s stock worth $9,054,000 after buying an additional 21,234 shares during the period. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other REGENXBIO news, Director Kenneth T. Mills sold 20,602 shares of the firm’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.91, for a total value of $162,961.82. Following the completion of the sale, the director now directly owns 475,103 shares in the company, valued at $3,758,064.73. This trade represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 12.79% of the stock is owned by insiders.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.